Cargando…

Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most common coronavirus that causes large-scale infections worldwide. Currently, several studies have shown that the ABO blood group is associated with coronavirus disease 2019 (COVID-19) infection and some studies have also...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xianfei, Fan, Hongyan, Kou, Jinxin, Lu, Dongxue, Huang, Fang, Meng, Xi, Liu, Haiying, Li, Zhuo, Tang, Mei, Zhang, Jing, Liu, Nannan, Hu, Xingbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327892/
https://www.ncbi.nlm.nih.gov/pubmed/37425304
http://dx.doi.org/10.3389/fmed.2023.1167452
_version_ 1785069693557538816
author Zeng, Xianfei
Fan, Hongyan
Kou, Jinxin
Lu, Dongxue
Huang, Fang
Meng, Xi
Liu, Haiying
Li, Zhuo
Tang, Mei
Zhang, Jing
Liu, Nannan
Hu, Xingbin
author_facet Zeng, Xianfei
Fan, Hongyan
Kou, Jinxin
Lu, Dongxue
Huang, Fang
Meng, Xi
Liu, Haiying
Li, Zhuo
Tang, Mei
Zhang, Jing
Liu, Nannan
Hu, Xingbin
author_sort Zeng, Xianfei
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most common coronavirus that causes large-scale infections worldwide. Currently, several studies have shown that the ABO blood group is associated with coronavirus disease 2019 (COVID-19) infection and some studies have also suggested that the infection of COVID-19 may be closely related to the interaction between angiotensin-converting enzyme 2 (ACE2) and blood group antigens. However, the relationship between blood type to clinical outcome in critically ill patients and the mechanism of action is still unclear. The current study aimed to examine the correlation between blood type distribution and SARS-CoV-2 infection, progression, and prognosis in patients with COVID-19 and the potential mediating role of ACE2. With 234 patients from 5 medical centers and two established cohorts, 137 for the mild cohort and 97 for the critically ill cohort, we found that the blood type A population was more sensitive to SARS-CoV-2, while the blood type distribution was not relevant to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality in COVID-19 patients. Further study showed that the serum ACE2 protein level of healthy people with type A was significantly higher than that of other blood groups, and type O was the lowest. The experimental results of spike protein binding to red blood cells also showed that the binding rate of people with type A was the highest, and that of people with type O was the lowest. Our finding indicated that blood type A may be the biological marker for susceptibility to SARS-CoV-2 infection and may be associated with potential mediating of ACE2, but irrelevant to the clinical outcomes including ARDS, AKI, and death. These findings can provide new ideas for clinical diagnosis, treatment, and prevention of COVID-19.
format Online
Article
Text
id pubmed-10327892
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103278922023-07-08 Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2 Zeng, Xianfei Fan, Hongyan Kou, Jinxin Lu, Dongxue Huang, Fang Meng, Xi Liu, Haiying Li, Zhuo Tang, Mei Zhang, Jing Liu, Nannan Hu, Xingbin Front Med (Lausanne) Medicine Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most common coronavirus that causes large-scale infections worldwide. Currently, several studies have shown that the ABO blood group is associated with coronavirus disease 2019 (COVID-19) infection and some studies have also suggested that the infection of COVID-19 may be closely related to the interaction between angiotensin-converting enzyme 2 (ACE2) and blood group antigens. However, the relationship between blood type to clinical outcome in critically ill patients and the mechanism of action is still unclear. The current study aimed to examine the correlation between blood type distribution and SARS-CoV-2 infection, progression, and prognosis in patients with COVID-19 and the potential mediating role of ACE2. With 234 patients from 5 medical centers and two established cohorts, 137 for the mild cohort and 97 for the critically ill cohort, we found that the blood type A population was more sensitive to SARS-CoV-2, while the blood type distribution was not relevant to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality in COVID-19 patients. Further study showed that the serum ACE2 protein level of healthy people with type A was significantly higher than that of other blood groups, and type O was the lowest. The experimental results of spike protein binding to red blood cells also showed that the binding rate of people with type A was the highest, and that of people with type O was the lowest. Our finding indicated that blood type A may be the biological marker for susceptibility to SARS-CoV-2 infection and may be associated with potential mediating of ACE2, but irrelevant to the clinical outcomes including ARDS, AKI, and death. These findings can provide new ideas for clinical diagnosis, treatment, and prevention of COVID-19. Frontiers Media S.A. 2023-06-23 /pmc/articles/PMC10327892/ /pubmed/37425304 http://dx.doi.org/10.3389/fmed.2023.1167452 Text en Copyright © 2023 Zeng, Fan, Kou, Lu, Huang, Meng, Liu, Li, Tang, Zhang, Liu and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zeng, Xianfei
Fan, Hongyan
Kou, Jinxin
Lu, Dongxue
Huang, Fang
Meng, Xi
Liu, Haiying
Li, Zhuo
Tang, Mei
Zhang, Jing
Liu, Nannan
Hu, Xingbin
Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2
title Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2
title_full Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2
title_fullStr Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2
title_full_unstemmed Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2
title_short Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2
title_sort analysis between abo blood group and clinical outcomes in covid-19 patients and the potential mediating role of ace2
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327892/
https://www.ncbi.nlm.nih.gov/pubmed/37425304
http://dx.doi.org/10.3389/fmed.2023.1167452
work_keys_str_mv AT zengxianfei analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT fanhongyan analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT koujinxin analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT ludongxue analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT huangfang analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT mengxi analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT liuhaiying analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT lizhuo analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT tangmei analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT zhangjing analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT liunannan analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2
AT huxingbin analysisbetweenabobloodgroupandclinicaloutcomesincovid19patientsandthepotentialmediatingroleoface2